Fluad Vaccine Description
Fluad consists of an inactivated, trivalent influenza virus antigen produced in eggs and an oil-in-water emulsion adjuvant, MF59. Adding MF59 adjuvant to an influenza vaccine is designed to enhance the immune response to the influenza strains contained in the vaccine in adults 65 years and older.
Fluad was the first FDA-approved seasonal flu shot that contains an adjuvant, which is an immune-enhancing ingredient.
For 2020-2021, trivalent (three-component) egg-based vaccines are recommended to contain:
- A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus (updated)
- A/Hong Kong/2671/2019 (H3N2)-like virus (updated)
- B/Washington/02/2019 (B/Victoria lineage)-like virus (updated)
The immune-enhancing ingredient in Fluad is an oil derived from squalene. Squalene is a naturally occurring substance found in humans, animals, and plants.
Squalene the immune-enhancing ingredient is proven to provide a strong immune response to help the immune systems of adults 65 and older to recognize and respond to the flu virus.
Fluad vaccine has an extensive clinical legacy, with 144+ million doses distributed and licensure in 30 countries since it was first approved in 1997.
Seqirus is part of CSL Limited. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
Fluad Vaccine Indication
Fluad is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
Fluad helps protect against the same flu strains as other seasonal flu shots, but it has something they don’t have: an immune-enhancing ingredient that can help provide a strong immune response to the flu in adults 65 and older. Seniors who have an aging immune system might have a lower immune response to traditional flu vaccines compared to younger adults.
Fluad Vaccine Dosage
Fluad is administered as an intramuscular injection in adults 65 years of age and older.
Fluad Vaccine Adverse Events
Some adverse events (which are also reported after regular flu vaccines) were reported more frequently after vaccination with Fluad. The most experienced during clinical studies were mild to moderate and temporary: pain, redness at the injection site, headache, muscle aches, and malaise.
Fluad Vaccine News
September 21, 2020 - Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence that demonstrated an MF59® adjuvanted, trivalent influenza vaccine was more effective than a standard-dose non-adjuvanted trivalent seasonal vaccine in preventing influenza-related medical office visits and hospitalizations in adults 65 years and older during the 2017/18 U.S. influenza season.
August 7, 2020 - Study: Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season.
February 24, 2020 - Seqirus Receives FDA Approval for FLUAD QUADRIVALENT for Adults 65 Years and Older.
July 20, 2017 - Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market.